-
Mashup Score: 0Jennifer Soung, MD: Findings on Guselkumab for Psoriasis Among Patients with Diverse Skin Types - 3 month(s) ago
In this discussion, Soung discusses the VISIBLE study results on guselkumab and its design for individuals of diverse skin tones.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
In this interview, Remo Panaccione, MD, discusses results from the long-term extension of the GALAXI phase 2 study for guselkumab in Crohn disease and their implications in clinical practice.
Source: www.hcplive.comCategories: General Medicine News, General NewsTweet-
We sat down with @RPanaccione to discuss findings from the long-term extension of the GALAXI phase 2 study for #guselkumab in adults with Crohn disease. Watch the full interview: https://t.co/kaoget4rKF https://t.co/DdiTPkhPN7
-
-
Mashup Score: 0Skin Efficacy Linked to Nail Response in Guselkumab Treatment - 7 month(s) ago
In patients receiving guselkumab, achieving NAPSI 0/1 at week 24 and week 48 was associated with lower baseline NAPSI and week 16 PASI.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
In patients receiving #guselkumab, achieving NAPSI 0/1 at week 24 and week 48 was associated with lower baseline NAPSI and week 16 PASI. https://t.co/6K5noKmO4Z
-
-
Mashup Score: 1Guselkumab Produces Long-Lasting Pharmacodynamic Effects, Disease Improvement in PsA - 7 month(s) ago
Continued reductions in serum acute phase proteins and collagen degradation proteins observed in patients with psoriatic arthritis receiving guselkumab may be linked to sustained symptom improvements.
Source: www.hcplive.comCategories: Latest Headlines, RheumatologyTweet-
Sustainable pharmacodynamic effects, improvements in disease activity, and significant reductions in serum cytokines and collagen degradation proteins were observed in patients with #PsoriaticArthritis receiving long-term #guselkumab treatment. https://t.co/sTDPPv7Dsm
-
-
Mashup Score: 0
At week 24, patients receiving guselkumab had significant decreases in C-reactive protein and effector cytokines linked to the interleukin-23 (IL-23)/IL-17 levels compared with patients in the placebo cohort.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet-
At week 24, patients with #PsoriaticArthritis receiving #guselkumab had significant decreases in CRP and effector cytokines linked to the IL-23/IL-17 levels compared with patients in the placebo cohort. https://t.co/ygqwHVVYtw
-
At week 24, patients with #PsoriaticArthritis receiving #guselkumab had significant decreases in CRP and effector cytokines linked to the IL-23/IL-17 levels compared with patients in the placebo cohort. https://t.co/3it0QTDJLW
-
-
Mashup Score: 1Good News on Guselkumab - 10 month(s) ago
Drug improved PsA through 1-year mark, even in those who previously took TNFis
Source: www.medpagetoday.comCategories: Latest Headlines, RheumatologyTweet-
RT @medpagetoday: What is the next clinical frontier for #guselkumab? #Rheumatology @ACRheum Read more: https://t.co/BfjncUGkfg https://t…
-
-
Mashup Score: 0Good News on Guselkumab - 10 month(s) ago
Drug improved PsA through 1-year mark, even in those who previously took TNFis
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
What is the next clinical frontier for #guselkumab? #Rheumatology @ACRheum Read more: https://t.co/BfjncUGkfg https://t.co/zeUr62Iw5s
-
-
Mashup Score: 0Guselkumab Safety Profile Consistent for Psoriasis, PsA at 5 Years - 12 month(s) ago
An analysis of 11 late-stage clinical trials shows guselkumab provides a consistent and comparable safety profile to placebo in treated patients.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
What clinicians believe to be the most comprehensive safety analysis of #guselkumab to date shows the IL-23 inhbitor is consistently safe through 5 years in patients with psoriatic disease. From #CCREast: https://t.co/wZoCqSXFr5 https://t.co/lX3gP1s1aL
-
-
Mashup Score: 1Soumya Chakravarty, MD, PhD: Guselkumab Demonstrates Long-Term Efficacy in Treating PsA - 1 year(s) ago
Soumya Chakravarty, MD, PhD, discussed the results of the DISCOVER-1 and DISCOVER-2 studies that evaluated the long-term efficacy of guselkumab for the treatment of adult patients with active psoriatic arthritis.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
Soumya Chakravarty, MD, PhD, discussed the results of the DISCOVER-1 and DISCOVER-2 studies that evaluated the long-term efficacy of #guselkumab for the treatment of adult patients with active #PsoriaticArthritis. https://t.co/ia5Ep3YugQ https://t.co/K1FtxoOCqH
-
-
Mashup Score: 0Guselkumab Deemed Safe, Effective Treatment for TNFi-Experienced Patients with Psoriatic Arthritis - 1 year(s) ago
Results demonstrate that guselkumab was well-tolerated in studies continuing for 1 to 2 years among patients with active psoriatic arthritis regardless of TNFi experience.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Results demonstrate that #guselkumab was well-tolerated in studies continuing for 1 to 2 years among patients with active #PsoriaticArthritis regardless of TNFi experience. Check out the story here: https://t.co/dbCYiABsUY
-
A new informative interview with Dr. Jennifer Soung of @SoCalDermTrials covers recent findings from the VISIBLE study on #guselkumab. In this discussion, Dr. Soung discusses the importance of addressing the needs of patients with diverse skin tones. https://t.co/q0ilxWKn8p